Who Makes Wegovy and Ozempic?
Both drugs are made by Novo Nordisk. They contain the same active ingredient, semaglutide, a GLP-1 receptor agonist that mimics a hormone to reduce appetite, slow stomach emptying, and improve blood sugar control.[1]
Key FDA Approvals and Uses
Ozempic is approved for type 2 diabetes management in adults, with weight loss as a common side effect. Wegovy is approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like hypertension. Off-label use of Ozempic for weight loss is widespread but not its primary indication.[1][2]
Dosage Differences for Weight Loss
Wegovy starts at 0.25 mg weekly and titrates up to a maximum 2.4 mg weekly dose, optimized for weight loss. Ozempic starts at 0.25 mg and maxes at 2 mg weekly for diabetes, though some doctors prescribe higher off-label doses up to 2.4 mg for weight loss. Higher doses generally lead to more weight reduction, but Wegovy's dosing schedule supports that goal directly.[1][3]
| Aspect | Wegovy | Ozempic |
|--------|--------|---------|
| Max Weekly Dose | 2.4 mg | 2 mg (official); up to 2.4 mg off-label |
| Pen Design | Multi-dose with higher capacity | Multi-dose, lower max fill |
| Titration Steps | 6 steps to 2.4 mg | 4 steps to 2 mg |
Weight Loss Effectiveness
Clinical trials show Wegovy users lose 15-20% of body weight over 68 weeks at full dose. Ozempic trials for diabetes report 10-15% loss, but real-world off-label use can match Wegovy at equivalent doses. Wegovy's higher approved dose and weight-focused trials give it an edge for non-diabetics seeking maximum loss.[3][4]
Side Effects and Safety
Both cause similar issues: nausea, vomiting, diarrhea, constipation, and abdominal pain, mostly during dose increases. Serious risks like pancreatitis, gallbladder problems, or thyroid tumors apply to both. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies. No major differences, but insurance scrutiny on Ozempic for weight loss can limit access.[1][2]
Cost and Insurance Coverage
Wegovy lists at $1,349 per month before insurance; Ozempic at $936. Coverage favors Ozempic for diabetes but often denies Wegovy for weight loss unless criteria are met. Patient assistance programs exist for both, and compounding versions (semaglutic) are cheaper but riskier due to FDA shortages and quality concerns.[5]
Availability and Supply Issues
Both faced shortages in 2023-2024 from demand. Ozempic pens are more widely stocked for diabetes patients. Wegovy has compounded alternatives more readily available during backorders.[2]
When to Choose One Over the Other
Pick Wegovy for dedicated weight loss with obesity—it's purpose-built with better insurance paths in some plans for that use. Use Ozempic if you have diabetes or need a lower max dose/cost. Consult a doctor; neither is first-line without lifestyle changes.[1][3]
Sources
[1] FDA: Semaglutide (Ozempic, Wegovy) Information
[2] Ozempic Prescribing Information (Novo Nordisk)
[3] Wegovy Prescribing Information (Novo Nordisk)
[4] NEJM: STEP 1 Trial (Wegovy)
[5] GoodRx: Semaglutide Pricing